The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Table of Contents
Global Oncology Anti-Cancer Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Oncology Anti-Cancer Drugs Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Assessment by Type
2.1 Chemotherapy Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.2 Targeted Therapy Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.3 Immunotherapy (Biologic Therapy) Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.4 Hormonal Therapy Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.5 Others Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific Oncology Anti-Cancer Drugs Market Assessment by Type
3.1 Asia Pacific Market Performance (Sales, Revenue)
3.2 Key Players in Asia Pacific
4 North America Oncology Anti-Cancer Drugs Market Assessment by Type
4.1 North America Market Performance (Sales, Revenue)
4.2 Key Players in North America
5 Europe Oncology Anti-Cancer Drugs Market Assessment by Type
4.1 Europe Market Performance (Sales, Revenue)
4.2 Key Players in Europe
6 South America Oncology Anti-Cancer Drugs Market Assessment by Type
4.1 South America Market Performance (Sales, Revenue)
4.2 Key Players in South America
7 Middle Easr and Africa Oncology Anti-Cancer Drugs Market Assessment by Type
4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
4.2 Key Players in Middle Easr and Africa
8 World Oncology Anti-Cancer Drugs Market Assessment by Type
8.1 Asia Pacific Oncology Anti-Cancer Drugs Market Assessment by Application (Consumption and Market Share)
8.2 North America Oncology Anti-Cancer Drugs Market Assessment by Application (Consumption and Market Share)
8.3 Europe Oncology Anti-Cancer Drugs Market Assessment by Application (Consumption and Market Share)
8.4 South America Oncology Anti-Cancer Drugs Market Assessment by Application (Consumption and Market Share)
8.5 Middle East and Africa Oncology Anti-Cancer Drugs Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
9.1 Amgen
9.1.1 Amgen Profiles
9.1.2 Amgen Product Portfolio
9.1.3 Amgen Oncology Anti-Cancer Drugs Business Performance
9.1.4 Amgen Oncology Anti-Cancer Drugs Business Development and Market Status
9.2 AstraZeneca
9.2.1 AstraZeneca Profiles
9.2.2 AstraZeneca Product Portfolio
9.2.3 AstraZeneca Oncology Anti-Cancer Drugs Business Performance
9.2.4 AstraZeneca Oncology Anti-Cancer Drugs Business Development and Market Status
9.3 Roche Diagnostics
9.3.1 Roche Diagnostics Profiles
9.3.2 Roche Diagnostics Product Portfolio
9.3.3 Roche Diagnostics Oncology Anti-Cancer Drugs Business Performance
9.3.4 Roche Diagnostics Oncology Anti-Cancer Drugs Business Development and Market Status
9.4 GlaxoSmithKline
9.4.1 GlaxoSmithKline Profiles
9.4.2 GlaxoSmithKline Product Portfolio
9.4.3 GlaxoSmithKline Oncology Anti-Cancer Drugs Business Performance
9.4.4 GlaxoSmithKline Oncology Anti-Cancer Drugs Business Development and Market Status
9.5 Merck
9.5.1 Merck Profiles
9.5.2 Merck Product Portfolio
9.5.3 Merck Oncology Anti-Cancer Drugs Business Performance
9.5.4 Merck Oncology Anti-Cancer Drugs Business Development and Market Status
9.6 Novartis
9.6.1 Novartis Profiles
9.6.2 Novartis Product Portfolio
9.6.3 Novartis Oncology Anti-Cancer Drugs Business Performance
9.6.4 Novartis Oncology Anti-Cancer Drugs Business Development and Market Status
9.7 AbbVie
9.7.1 AbbVie Profiles
9.7.2 AbbVie Product Portfolio
9.7.3 AbbVie Oncology Anti-Cancer Drugs Business Performance
9.7.4 AbbVie Oncology Anti-Cancer Drugs Business Development and Market Status
9.8 Sanofi
9.8.1 Sanofi Profiles
9.8.2 Sanofi Product Portfolio
9.8.3 Sanofi Oncology Anti-Cancer Drugs Business Performance
9.8.4 Sanofi Oncology Anti-Cancer Drugs Business Development and Market Status
9.9 EIMC United Pharmaceuticals
9.9.1 EIMC United Pharmaceuticals Profiles
9.9.2 EIMC United Pharmaceuticals Product Portfolio
9.9.3 EIMC United Pharmaceuticals Oncology Anti-Cancer Drugs Business Performance
9.9.4 EIMC United Pharmaceuticals Oncology Anti-Cancer Drugs Business Development and Market Status
9.10 Actavis
9.10.1 Actavis Profiles
9.10.2 Actavis Product Portfolio
9.10.3 Actavis Oncology Anti-Cancer Drugs Business Performance
9.10.4 Actavis Oncology Anti-Cancer Drugs Business Development and Market Status
10 World Oncology Anti-Cancer Drugs Market Assessment by Players
10.1 Global Oncology Anti-Cancer Drugs Sales (K Units) and Market Share by Players 2014-2020
10.2 Global Oncology Anti-Cancer Drugs Revenue (M USD) and Market Share by Players 2014-2020
10.3 Global Oncology Anti-Cancer Drugs Price (USD/Unit) of Players 2014-2020
10.4 Global Oncology Anti-Cancer Drugs Gross Margin of Players 2014-2020
10.5 Market Concentration
11 Regional Market Performance by Segment of Players
11.1 North America
11.1.1 North America Oncology Anti-Cancer Drugs Sales Assessment of Players 2014-2020
11.1.2 North America Oncology Anti-Cancer Drugs Revenue Assessment of Players 2014-2020
11.1.3 North America Oncology Anti-Cancer Drugs Price Assessment of Players 2014-2020
11.1.4 North America Oncology Anti-Cancer Drugs Gross Margin Assessment of Players 2014-2020
11.1.5 Market Concentration
11.2 Europe
11.2.1 Europe Oncology Anti-Cancer Drugs Sales Assessment of Players 2014-2020
11.2.2 Europe Oncology Anti-Cancer Drugs Revenue Assessment of Players of Manufacturers 2014-2020
11.2.3 Europe Oncology Anti-Cancer Drugs Price Assessment of Players 2014-2020
11.2.4 Europe Oncology Anti-Cancer Drugs Gross Margin Assessment of Players 2014-2020
11.2.5 Market Concentration
11.3 Asia-Pacific Market Performance for Manufacturers
11.3.1 Asia-Pacific Oncology Anti-Cancer Drugs Sales Assessment of Players 2014-2020
11.3.2 Asia-Pacific Oncology Anti-Cancer Drugs Revenue Assessment of Players 2014-2020
11.3.3 Asia-Pacific Oncology Anti-Cancer Drugs Price Assessment of Players 2014-2020
11.3.4 Asia-Pacific Oncology Anti-Cancer Drugs Gross Margin Assessment of Players 2014-2020
11.3.5 Market Concentration
11.4 South America Market Performance for Players
11.4.1 South America Oncology Anti-Cancer Drugs Sales Assessment of Players 2014-2020
11.4.2 South America Oncology Anti-Cancer Drugs Revenue Assessment of Players 2014-2020
11.4.3 South America Oncology Anti-Cancer Drugs Price Assessment of Players 2014-2020
11.4.4 South America Oncology Anti-Cancer Drugs Gross Margin Assessment of Players 2014-2020
11.4.5 Market Concentration
11.5 Middle East and Africa Market Performance for Players
11.5.1 Middle East and Africa Oncology Anti-Cancer Drugs Sales Assessment of Players 2014-2020
11.5.2 Middle East and Africa Oncology Anti-Cancer Drugs Revenue Assessment of Players 2014-2020
11.5.3 Middle East and Africa Oncology Anti-Cancer Drugs Price Assessment of Players 2014-2020
11.5.4 Middle East and Africa Oncology Anti-Cancer Drugs Gross Margin Assessment of Players 2014-2020
11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
12.1 Asia Pacific
12.1.1 Asia Pacific Oncology Anti-Cancer Drugs Sales by Countries/Regions 2014-2020
12.1.2 Asia Pacific Oncology Anti-Cancer Drugs Revenue by Countries/Regions 2014-2020
12.1.3 Asia Pacific Oncology Anti-Cancer Drugs Average Price by Countries/Regions 2014-2020
12.2 North America
12.2.1 North America Oncology Anti-Cancer Drugs Sales by Countries/Regions 2014-2020
12.2.2 North America Oncology Anti-Cancer Drugs Revenue by Countries/Regions 2014-2020
12.2.3 North America Oncology Anti-Cancer Drugs Average Price by Countries/Regions 2014-2020
12.3 Europe
12.3.1 Europe Oncology Anti-Cancer Drugs Sales by Countries/Regions 2014-2020
12.3.2 Europe Oncology Anti-Cancer Drugs Revenue by Countries/Regions 2014-2020
12.3.3 Europe Oncology Anti-Cancer Drugs Average Price by Countries/Regions 2014-2020
12.4 South America
12.4.1 South America Oncology Anti-Cancer Drugs Sales by Countries/Regions 2014-2020
12.4.2 South America Oncology Anti-Cancer Drugs Revenue by Countries/Regions 2014-2020
12.4.3 South America Oncology Anti-Cancer Drugs Average Price by Countries/Regions 2014-2020
12.5 Middle East and Africa
12.5.1 Middle East and Africa Oncology Anti-Cancer Drugs Sales by Countries/Regions 2014-2020
12.5.2 Middle East and Africa Oncology Anti-Cancer Drugs Revenue by Countries/Regions 2014-2020
12.5.3 Middle East and Africa Oncology Anti-Cancer Drugs Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
13.1 Technology
13.2 Market Opportunity
14 World Oncology Anti-Cancer Drugs Sales & Revenue Forecast 2021-2026
14.1 World Oncology Anti-Cancer Drugs Sales and Revenue Forecast by Regions 2021-2026
14.1.1 World Oncology Anti-Cancer DrugsSales and Market Share by Regions
14.1.2 World Oncology Anti-Cancer DrugsRevenue and Market Share by Regions
15 Asia Oncology Anti-Cancer Drugs Market Forecast 2021-2026
15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
15.1.1 Chemotherapy
15.1.2 Targeted Therapy
15.1.3 Immunotherapy (Biologic Therapy)
15.1.4 Hormonal Therapy
15.1.5 Others
15.2 Consumption Forecast by Application, 2021-2026
16 North America Oncology Anti-Cancer Drugs Market Forecast 2021-2026
16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
16.1.1 Chemotherapy
16.1.2 Targeted Therapy
16.1.3 Immunotherapy (Biologic Therapy)
16.1.4 Hormonal Therapy
16.1.5 Others
16.2 Consumption Forecast by Application, 2021-2026
17 Europe Oncology Anti-Cancer Drugs Market Forecast 2021-2026
17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
17.1.1 Chemotherapy
17.1.2 Targeted Therapy
17.1.3 Immunotherapy (Biologic Therapy)
17.1.4 Hormonal Therapy
17.1.5 Others
17.2 Consumption Forecast by Application, 2021-2026
18 South America Oncology Anti-Cancer Drugs Market Forecast 2021-2026
18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
18.1.1 Chemotherapy
18.1.2 Targeted Therapy
18.1.3 Immunotherapy (Biologic Therapy)
18.1.4 Hormonal Therapy
18.1.5 Others
18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa Oncology Anti-Cancer Drugs Market Forecast 2021-2026
19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
19.1.1 Chemotherapy
19.1.2 Targeted Therapy
19.1.3 Immunotherapy (Biologic Therapy)
19.1.4 Hormonal Therapy
19.1.5 Others
19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
20.1 Global Oncology Anti-Cancer Drugs Price (USD/Unit) Trend 2021-2026
20.2 Global Oncology Anti-Cancer Drugs Gross Profit Trend 2021-2026
21 Conclusion
Price : US$ 3,500 | Date : Apr 2024 |
Category : Manufacturing and Construction | Pages : 139 |
Price : US$ 3,500 | Date : Apr 2024 |
Category : Services | Pages : 120 |
Price : US$ 3,500 | Date : Apr 2024 |
Category : Manufacturing and Construction | Pages : 125 |
Price : US$ 3,500 | Date : Apr 2024 |
Category : Services | Pages : 150 |
Price : US$ 3,500 | Date : Apr 2024 |
Category : Manufacturing and Construction | Pages : 123 |
We will be happy to help you find what you need. Please call us or write to us: